Navigation Links
New Research Has Found Another Use For Botox

Botox not only helps in smoothening out wrinkles but results from a long-term study show a Botox injection helps restore the voices of people with // a voice disorder caused by spasms in their vocal cord muscles. Spasmodic Dysphonia usually affects adults, typically starting in mid-adulthood, and women are more prone to develop it. Severity of symptoms can vary from day to day and can be affected by fatigue or anxiety.

Botox has been used off-label for years to help people with spasmodic dysphonia, a rare and often-misdiagnosed voice disorder that makes the voice sound strained, broken or breathy. The shots relax the muscles in the vocal cords, just as they do to the muscles in the face of those who use Botox for cosmetic purposes.

Nearly all of the 36 patients with spasmodic dysphonia showed dramatic and reproducible improvement on their quality of life questionnaires, which surveyed voice, emotional, social and physical functioning issues.On a scale of 100, with 100 being perfect, patients went from an average score of 30 before the first injection to an average score of about 80 after. Improvements continued with six injections. Thirty of the patients still receive injections twice a year.
'"/>




Page: 1

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Researchers urge caution in using ear tube surgery
3. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Research of Ritalin
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. A Compilation of recent Diabetes Research articles
9. Research on causes for falling helps develop preventive strategies
10. New standards for Human Research Safety
11. Research on Celiac Disease in children
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Research Has Found Another Use For Botox

(Date:5/22/2008)... PHOENIX, May 22 /PRNewswire/ -- TriWest Heal...Telly Awards in the 28th Annual Telly Awards,compe...r the visual arts,community., The awards recogniz...ideo as an effective medium to reach military serv...sources and clinical support tools., "At TriWest,...
(Date:5/22/2008)... IRVINE, Calif., May 22 /PRNewswire/ -- Accen...een formally accepted into Sun,s Authorized,Subcon...Delivery Workforce,to provide improved integration...w relationship, Accenx Technologies will see subst...nt roster, develop a closer working,relationship w...
(Date:5/22/2008)... , LOS ANGELES, May 22 /PRNewswire-USNewswire/ -...used on prevention and recovery from Autism,ADHD ... of the organization,through three major steps:, ...ave joined the Board,of Directors., Ms. McCarthy ...other,who recovered her son Evan from autism. Her ...
(Date:5/22/2008)... First Product That Gives Consumers an All-Natura...robiotics & Prebiotic Fiber, JERICHO, N.Y., May 2...ottage cheese with more healthy benefits hits supe...e Health Cottage Cheese with Pro-Active,Nutrients....ed All-Natural,cottage cheese product, Friendship ...
Breaking Medicine News(10 mins):Health News:TriWest Receives National Awards for Innovative Video Communications to Military Community 2Health News:TriWest Receives National Awards for Innovative Video Communications to Military Community 3Health News:Accenx Technologies Joins Sun's Authorized Subcontractor Program 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 3Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 2Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 3
...s among children that were known until now were ch...y recently, researchers and neurologists have foun... ailments //in newborns that often go unnoticed. A...na Ferriero, Chief of Neurology at the University ...
...on University School of Medicine have tried a new ...urpura(TPP), which has offered great hope. TPP is ...s in the blood clotting system is missing. This pr...ne of the other clotting proteins sticks to itself...
...e looking up for a long time, like painting, plumb...However, a new product called Necprotech developed...p// reduce neck strain by a third. The product was... clinging to a rock wall look easy, but a slip fiv...
...nce of keeping a clean environment and self to le...us are not aware that just a simple habit of hand ...ctions. Everyday life does not involve// many acti...m heavy house work and gardening, and this is prob...
Other Medicine News:Health News:Stroke also in list of common childhood ailments 2
(Date:5/21/2008)...rom CHARM Study in Remission at One Year ...T PARK, Ill., May 21 /- Res...ott pivotal studies, CHARM and GAIN,demonstrate t...ted with,HUMIRA(R) (adalimumab) achieved long-term...ively, according to data presentations today at Di...
(Date:5/21/2008)...ighlight Watson,s commitment to urology - ..., Fla., May 21 /- Watson Ph...alty pharmaceutical company, announced,today that ... 3 products at,the American Urological Association... safety trial involving silodosin, an investigatio...
(Date:5/21/2008).../ -- Alba Therapeutics Corporation,announced today...presented,in the Clinical Advances in Celiac Disea...ting in San Diego, California. Results of the rand... larazotide acetate for the,prevention of celiac d...subjects in remission(1) were presented by Daniel ...
(Date:5/21/2008)...long-term survivors validate Jennerex ...SCO and YONGIN-SI, South Korea, May 21 /PRNewswire... Ontario), and its South,Korean partner Green Cros...al results from its first-in-class lead product JX...Oncology. The majority of these end- stage,patient...
Breaking Medicine Technology:Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 2Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 3Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 4Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 5Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 2Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 3Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 4Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 1Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 2Younger Adults Increasingly Treated for Heart Disease related Conditions 694 1Younger Adults Increasingly Treated for Heart Disease related Conditions 694 2Younger Adults Increasingly Treated for Heart Disease related Conditions 694 3Younger Adults Increasingly Treated for Heart Disease related Conditions 694 4P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 1P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 2P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 3P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 4P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 5P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 6P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 7P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 8P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 9P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 10P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 11P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 12P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 13P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 14P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 15P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 16Elan Pharmaceuticals Inc Licenses Software and Databases From GeneGo 4948 1
... /PRNewswire-FirstCall/ --,Alfacell Corporation,s ...s a potent payload in antibody conjugates for canc... Handbook of Therapeutic,Antibodies. , In a chapte...ybak, Ph.D. summarizes preclinical research indica...improves in a number of tumor,models, including no...
...PRNewswire/ -- Treatment of,coronary artery diseas...ient setting, according to a study published today...pitalization rates for heart attacks (acute myocar...to 2005, possibly due,to broader use of preventive...ell as declines in risk factors like smoking. , Th...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
...r transfusion needs. A recognized leader in autotr...ay to add the safety of microfiltration for a vari...ve or postoperative applications, autologous or ho...rovides both convenience and versatility in the re...
This high technology cast plaster cutter saw is very easy and comfortable to use.
Designed to reduce noise to a minimum results in less emotional trauma for patients and less hearing trauma for the clinician. The innovative motor plus saw design delivers high power in a smaller, l
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws.
Medicine Products: